Perrigo Stands Alone At Top OF OTC Private Label Market, In Hunt For More Deals
This article was originally published in The Tan Sheet
Executive Summary
The failure of Mylan’s tender closes a bitter seven-month long battle marked by Perrigo litigation filed to block the tender and by orders from Irish securities regulators for Perrigo to correct or clarify its comments about Mylan’s offer. CEO Joseph Papa looks to Europe to add more consumer product business.
You may also be interested in...
Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount
Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.
Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount
Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.
Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier
Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.